Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)
- Conditions
- Sepsis
- Interventions
- Drug: PlaceboDrug: Emapalumab-Izsg
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Hellenic Institute for the Study of Sepsis
- Target Recruit Count
- 75
- Registration Number
- NCT06694701
- Locations
- 🇬🇷
1st Department of Internal Medicine, Thriasio Elefsis General Hospital, Elefsina, Attiki, Greece
🇬🇷4th Department of Internal Medicine, ATTIKON University General Hospital, Athens, Greece
🇬🇷Intensive Care Unit, Ippokrateio Athens General Hospital, Athens, Greece
The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated with the Post-acute Phase of the Infection by Covid-19
- Conditions
- Pulmonary ComplicationsCardiovascular ComplicationsRenal ComplicationsCOVID-19
- Interventions
- Other: Blood samplesOther: Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Hellenic Institute for the Study of Sepsis
- Target Recruit Count
- 345
- Registration Number
- NCT06608849
- Locations
- 🇬🇷
10th Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases, Athens, Greece
🇬🇷Obstructive Diseases Clinic, Sotiria Athens Hospital of Chest Diseases, Athens, Greece
🇬🇷1st Department of Internal Medicine, Thriasio General Hospital of Elefsina, Elefsina, Greece
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
- Conditions
- Pneumonia, Community-AcquiredCOVID-19 PneumoniaCardiovascular Diseases
- Interventions
- Other: Blood samples and Oropharyngeal swabOther: Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Hellenic Institute for the Study of Sepsis
- Target Recruit Count
- 650
- Registration Number
- NCT06601998
- Locations
- 🇬🇷
Intensive Care Unit 2, AHEPA University General Hospital of Thessaloniki, Thessaloniki, Greece
🇬🇷2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece
🇬🇷10th Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases, Athens, Greece
Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)
- Conditions
- Community-acquired Pneumonia
- Interventions
- Drug: Tablets
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Hellenic Institute for the Study of Sepsis
- Target Recruit Count
- 330
- Registration Number
- NCT06294600
- Locations
- 🇬🇷
1st Department of Internal Medicine - General Hospital of Athens "Sismanogleio-Amalia Fleming", Athens, Greece
🇬🇷1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Athens, Greece
🇬🇷1st Department of Internal Medicine, EVANGELISMOS Athens General Hospital, Athens, Greece
NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification
- Conditions
- PneumoniaBacteremiaBiliary Tract InfectionAcute Pyelonephritis
- Interventions
- Diagnostic Test: NGS-based assay for bacterial identification
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Hellenic Institute for the Study of Sepsis
- Target Recruit Count
- 100
- Registration Number
- NCT06141395
- Locations
- 🇬🇷
4th Department of Internal Medicine,"Attikon" University Hospital, National and Kapodistrian University of Athens, Medical School, Chaïdári, Attiki, Greece
🇬🇷1st Department of Internal Medicine, General Hospital of Eleusis THRIASIO, Athens, Greece
🇬🇷3rd Department of Internal Medicine, General Hospital of Nikaia AGIOS PANTELEIMON, Nikaia, Greece
Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
- Conditions
- Long COVIDPost-Acute COVID-19 SyndromePost-Acute COVID-19
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hellenic Institute for the Study of Sepsis
- Target Recruit Count
- 182
- Registration Number
- NCT05926505
- Locations
- 🇩🇪
Out-patient long-COVID department, Jena University Hospital, Jena, Germany
🇬🇷Out-patient long-COVID department, Patras University General Hospital, Patra, Achaia, Greece
🇬🇷Out-patient long-COVID department III, Evangelismos Athens General Hospital, Athens, Attiki, Greece
Assessing the Procalcitonin-guidance and Molecular-guided Diagnosis for Therapy of Severe Infections (the MODIFY Trial)
- Conditions
- Sepsis
- Interventions
- Other: Standard of CareDiagnostic Test: Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results.
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Hellenic Institute for the Study of Sepsis
- Target Recruit Count
- 190
- Registration Number
- NCT05909683
- Locations
- 🇬🇷
3rd University Department of Internal Medicine, Sotiria Athens General Hospital, Athens, Greece
🇬🇷1st Department of Internal Medicine - General Hospital of Athens Sismanoglio- Amalia Fleming, Athens, Greece
🇬🇷3rd Department of Internal Medicine - General State Hospital of Nikaia "Saint Panteleimon" - West Attica General Hospital "Agia Varvara", Athens, Greece
Distinguishing Bacterial and Viral Infections by MeMed BV® Test to Limit Gut Colonization by MDRO
- Conditions
- Viral InfectionMulti-antibiotic ResistanceBacterial InfectionsRespiratory Tract Infections
- Interventions
- Diagnostic Test: MeMed BV®
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Hellenic Institute for the Study of Sepsis
- Target Recruit Count
- 230
- Registration Number
- NCT05897801
- Locations
- 🇬🇷
General Hospital of Elefsina 1st Department of Internal Medicine, ElefsÃna, Greece
🇬🇷Emergency Department of ATTIKON University General Hospital, Attiki, Chaidari, Greece
🇬🇷Emergency Department of Tzaneion General Hospital, Attiki, Piraeus, Greece
Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia
- Conditions
- Hospital-acquired PneumoniaCommunity-acquired Pneumonia
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Hellenic Institute for the Study of Sepsis
- Target Recruit Count
- 60
- Registration Number
- NCT05785442
- Locations
- 🇬🇷
6th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens, Athens, Greece
🇬🇷1st Department of Internal Medicine, General Hospital of Athens GENNIMATAS, Athens, Greece
🇬🇷3rd Department of Internal Medicine, General Hospital of Nikaia AGIOS PANTELEIMON, Nikaia, Greece
Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection
- Conditions
- Stool MicrobiomeOrgan Dysfunction SyndromeMortalityClostridioides Difficile Infection RecurrenceClostridioides Difficile Infection
- Interventions
- Drug: Normal saline 0.9% or 5% dextrose water
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Hellenic Institute for the Study of Sepsis
- Target Recruit Count
- 44
- Registration Number
- NCT05304715
- Locations
- 🇬🇷
2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupoli, Greece
🇬🇷2nd Department of Internal Medicine, Tzanneion General Hospital, Piraeus, Greece
🇬🇷1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloniki, Greece